Kalytera is a biopharmaceutical company focused on developing innovative therapies for various medical conditions. The company primarily works on cannabinoid-based treatments, aiming to improve patient outcomes in areas such as oncology and pain management. Founded in 2015, Kalytera is headquartered in New York City and has been involved in several clinical trials to assess the efficacy and safety of its products. The company seeks to leverage the therapeutic potential of cannabinoids, which are compounds found in the cannabis plant, to address unmet medical needs.